Aethlon Medical, Inc. (AEMD) Earnings Call Transcript & Summary

Yes. Proxies have been received for 399,752 of the total 711,136 shares of common stock outstanding on the record date. This represents approximately 56.21% of the total number of outstanding shares. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.

Thank you. Accordingly, we will now proceed with the formal business of this meeting. After all of the proposals have been described, we will answer any questions related to the proposals [Technical Difficulty]. As a reminder, we ask that any questions or comments during this portion of the meeting pertain only to these proposals. Please submit any questions as soon as possible for our review. There are 10 proposals to be considered by the stockholders of this meeting. The first item of business is the election of 5 directors to serve until the Annual Meeting of Stockholders in 2027 and until their successors are elected. The nominees for Director are Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti and Chetan S. Shah M.D. The second item of business today is the ratification of the appointment of Haskell & White LLP as our independent registered accounting firm for the fiscal year ending March 31, 2027. The third item of business is the approval of an issuance of up to 1,126,602 shares of the company's common stock issuable upon the exercise of common warrants and placement agent warrants issued pursuant to the company's offering in July '26. The fourth item of business is the approval of the compensation of our named chief -- named executive officers as disclosed in the proxy statement. The fifth item of business is the approval of an amendment to our 2020 Equity Incentive Plan, as amended, to increase the number of shares of our common stock authorized for issuance thereunder by 100,000 shares. The sixth item of business is the approval of an amendment to our articles of incorporation to increase the number of authorized shares of our common stock from 20 million to 200 million. The seventh item of business is the approval of an amendment to our Articles of Incorporation to authorize 20 million shares of preferred stock and to authorize the Board of Directors to establish one or more series thereof and to fix the designations, powers, preferences, rights, qualifications, limitations and restrictions of each such series. The eighth item of business is the approval of an issuance of the company's common stock or series convertible -- or securities convertible into or exercisable for shares of the company's common stock in connection with one or more future private financing transactions. The ninth item of business is the approval of an issuance of the company's common stock and/or securities exercisable for shares of the company's common stock in connection with one or more warrant exercise inducement transactions, including certain outstanding warrants of the company. And the tenth and final item of business is the approval of an adjournment of the annual meeting to another place or a later date or dates, if necessary or appropriate, to solicit additional proxies in the events we have not received sufficient votes in favor of any of the foregoing proposals. That was the final proposal for today's meeting. I will now take a moment to review any questions submitted regarding the proposals before we close the polls. As a reminder, we will only review and answer questions at this time that pertain to the proposals. I will now look for any questions. I do not see any questions. As there are no questions related to the proposals being presented to our stockholders for approval at today's meeting, the time is now 8:10 a.m. Pacific Time, and the polls are now closed for voting. May we have the results of the voting, please?

Based on the preliminary voting report, the results for the proposals presented at this meeting are as follows: the proposals to elect each of Edward Broenniman, James Frakes, Nicolas Gikakis, Angela Rossetti and Chetan Shah as Directors of the company is carried. The selection of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ended March 31, 2027, is approved. The proposal to approve an issuance of up to an aggregate of 1,126,602 shares of the company's common stock issuable upon the exercise of common warrants and placement agent warrants issued pursuant to the company's offering in July 2026 is approved. The proposal to approve the compensation of our named executive officers as disclosed in the proxy statement is approved. The proposal to approve an amendment to our 2020 Equity Incentive Plan as amended to increase the number of shares of our common stock authorized for issuance thereunder by 100,000 shares is approved. The proposal to approve an amendment to our articles of incorporation to increase the number of authorized shares of our common stock from 20 million to 200 million is approved. The approval to the amendment of our Articles of Incorporation to authorize 20 million shares of preferred stock and to authorize the Board of Directors to establish one or more series thereof and to fix the designations, powers, preferences, rights, qualifications, limitations and restrictions of each series is not approved. The proposal to approve the issuance of the company's common stock or securities convertible into or exercisable for shares of the company's common stock in connection with one or more future private financing transactions is approved. The proposal to approve an issuance of the company's common stock and/or securities exercisable for shares of the company's common stock in connection with one or more future warrant exercise inducement transaction involving certain outstanding warrants of the company is approved. The proposal to approve an adjournment of the annual meeting to another place or later date or dates, if necessary or appropriate, to solicit additional proxies in the event we have not received sufficient votes of the foregoing proposals is approved.

Thank you. Proposal #7 did not receive the vote required for approval and the remaining proposals presented for approval at today's meeting were approved by our stockholders. We will not be adjourning the meeting to another place or time, and we'll close out all matters of business at today's meeting. We expect to report our preliminary voting results or, if available to us on a timely basis, our final voting results on a current form on Form 8-K to be filed with the SEC within 4 business days after the end of this meeting. If not earlier reported, we expect to report our final voting results in an amendment to our Form 8-K within 4 business days after the final results are known to us. This concludes the formal portion of today's meeting, and the annual meeting is now concluded. We will now entertain any questions from stockholders. I will look again. I did not receive any questions. So I would like to thank everyone for attending today's virtual meeting and for your continued support of Aethlon Medical. Have a good day. Thank you very much. Goodbye.

This concludes today's conference, and you may disconnect at this time. Thank you for your participation.